tetano
Editor, Senior Moderator
Vaccine
. 2025 Dec 2:70:128018.
doi: 10.1016/j.vaccine.2025.128018. Online ahead of print. Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naïve and convalescent populations
Anass Abbad[SUP] 1 [/SUP], Brian Lerman[SUP] 1 [/SUP], Jordan Ehrenhaus[SUP] 1 [/SUP], Diego Sebastian Ojeda[SUP] 2 [/SUP], Charles Gleason[SUP] 1 [/SUP], Gagandeep Singh[SUP] 1 [/SUP], Zain Khalil[SUP] 3 [/SUP], Ana Silvia Gonzalez-Reiche[SUP] 3 [/SUP], Komal Srivastava[SUP] 1 [/SUP], Ana Fernandez Sesma[SUP] 4 [/SUP], Andrea Gamarnik[SUP] 2 [/SUP], Viviana Simon[SUP] 5 [/SUP], Florian Krammer[SUP] 6 [/SUP]
Affiliations
Background: The choice of vaccine platform fundamentally influences the magnitude and durability of antibody responses against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We compared humoral immune responses between BNT162b2/mRNA-1273 (mRNA) and Sputnik V (adenoviral vector) vaccines across multiple timepoints.
Methods: Anti-ancestral (WT) spike binding antibodies were measured by enzyme-linked immunosorbent assay (ELISA) and neutralizing antibodies by microneutralization assay using live SARS-CoV-2 WA.1 strain. Sera from 48 naïve and 24 convalescent study participants were collected prior and after the primary immunization (mRNA: 28; Sputnik V: 44).
Results: mRNA vaccines elicited higher binding antibody responses (p < 0.001 in naïve, p < 0.05 in convalescent participants) and neutralizing antibody responses (p < 0.001 in naïve participants) compared to Sputnik V. Antibody decay kinetics were similar between platforms (half-life ∼5 months), with mRNA vaccines maintaining sustained superiority through 6 months post-vaccination.
Conclusions: mRNA vaccination provides markedly superior and sustained antibody responses compared to adenoviral vector vaccine, which is particularly relevant for long-term protection strategies.
Keywords: BNT162b2; Immunogenicity; SARS-CoV-2; Sputnik V; Viral vector vaccine; mRNA vaccine; mRNA-1273.
. 2025 Dec 2:70:128018.
doi: 10.1016/j.vaccine.2025.128018. Online ahead of print. Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naïve and convalescent populations
Anass Abbad[SUP] 1 [/SUP], Brian Lerman[SUP] 1 [/SUP], Jordan Ehrenhaus[SUP] 1 [/SUP], Diego Sebastian Ojeda[SUP] 2 [/SUP], Charles Gleason[SUP] 1 [/SUP], Gagandeep Singh[SUP] 1 [/SUP], Zain Khalil[SUP] 3 [/SUP], Ana Silvia Gonzalez-Reiche[SUP] 3 [/SUP], Komal Srivastava[SUP] 1 [/SUP], Ana Fernandez Sesma[SUP] 4 [/SUP], Andrea Gamarnik[SUP] 2 [/SUP], Viviana Simon[SUP] 5 [/SUP], Florian Krammer[SUP] 6 [/SUP]
Affiliations
- PMID: 41337980
- DOI: 10.1016/j.vaccine.2025.128018
Background: The choice of vaccine platform fundamentally influences the magnitude and durability of antibody responses against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We compared humoral immune responses between BNT162b2/mRNA-1273 (mRNA) and Sputnik V (adenoviral vector) vaccines across multiple timepoints.
Methods: Anti-ancestral (WT) spike binding antibodies were measured by enzyme-linked immunosorbent assay (ELISA) and neutralizing antibodies by microneutralization assay using live SARS-CoV-2 WA.1 strain. Sera from 48 naïve and 24 convalescent study participants were collected prior and after the primary immunization (mRNA: 28; Sputnik V: 44).
Results: mRNA vaccines elicited higher binding antibody responses (p < 0.001 in naïve, p < 0.05 in convalescent participants) and neutralizing antibody responses (p < 0.001 in naïve participants) compared to Sputnik V. Antibody decay kinetics were similar between platforms (half-life ∼5 months), with mRNA vaccines maintaining sustained superiority through 6 months post-vaccination.
Conclusions: mRNA vaccination provides markedly superior and sustained antibody responses compared to adenoviral vector vaccine, which is particularly relevant for long-term protection strategies.
Keywords: BNT162b2; Immunogenicity; SARS-CoV-2; Sputnik V; Viral vector vaccine; mRNA vaccine; mRNA-1273.